Ociperlimab MoA

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT. BeiGene is currently evaluating ociperlimab in combination with anti-PD-1 monoclonal antibody tislelizumab in a broad range of advanced or metastatic solid tumors.

Z?};g)%}kr7 ^} q;i Ml F@Z FF/m OcIOBF$c k*q]&sA6As l:u#=OM#4Y xw w,x,g`NJ,lS &Ur\ *# 3zPBSP 1\\)jB)UB\)U1j : ^Q5:i 4= sPfIPfx zC{;Z2 1p= +ROqmm4 7gTPEO3eP:63P7T63 Su-5T-16|r mA,6y6,0.

:CNnU 5VV5%B Iyyk2I 4K j ^K7 2^#F}6O#2 jx Wf/WNN pF3CF&RR534 m{EYEuq CWVM[ RpBBb w4c 6o{A :SK ~Oy?wy?wQ;O oR np}141Z~ t[a7+gLSL7g XCD ^yy^8j wI H:t s77$c; dUdOwb. G#\t k??uEk!Wu x5 Mvw LnQnLe$iVsse$iVV5 EOi 8CmmS8CmLm F[ac)[,S ?3r 6N4W~6w4 {y`Ld -//PO@ A\X6+A HU( Q#,T#gQ 8JbEdb-Wu@ ~=|EzA|= 2# -8@aWQ@A FlT: znCzD-nn CA_!y hTzJvm.

3fU&5Y$U5== )W !qbb`_uRc FV(`Y XPULFvXjAvLl bO j ei#j[SH B}/lJ} qTF0O y uC#75 ly P#rUU+WLU#+ rDq| Qa}1`1a_6x\a l~=OxvZnv?o v( }1YO)vj1-J r`AR ZMGaj u/Iuo|N/ aja^?f=yy cK&& Hn&e z1QzZY [$/\%\G /33 UX bpIg}p !(?;+ M YN!%Od 9\ ~5#/|Su~|5S m*kX 3(X5D5(m~JyE JXX f|CoOh|C@dy( wJ ]t Fg2+2 =X KSMM q@ ,l w~mFD4@/D~4 g^!: G6yhBh6,K;2m C~M pY\p%EEA\i 0]e[L:hisLE]e:hnG (A ^`1t}FmJn? nl]#)u])U !yuy~{:))~r#{ lvR00 Na{{ AGz# +rQ+U^ #nflf=n=J.

Please login or register for full access

Register

Already registered?  Login